Publicação
Vitrolife private equity investment committee paper - business plan
| datacite.subject.fos | Ciências Sociais::Economia e Gestão | pt_PT |
| dc.contributor.advisor | Santos, Fábio | |
| dc.contributor.author | Berg, Laura | |
| dc.date.accessioned | 2024-12-10T14:59:52Z | |
| dc.date.available | 2024-12-10T14:59:52Z | |
| dc.date.issued | 2024-01-10 | |
| dc.date.submitted | 2023-12-20 | |
| dc.description.abstract | The target company, Vitrolife provides Medical Consumables, Technological Devices (C&T) and Genetic Testing services (GT) for in-vitro fertilization. C&T has a market size of SEK 15bn (CAGR of 14.3%) while GT’s market size is SEK 41bn (CAGR of 6.7%). Value creation is driven through an AI software partnership, the Eastern Europe Penetration and the acquisition of Virtus Health. Most of the value is driven by inorganic growth (50%). Based on a 16.7x exit multiple and an Enterprise Value of SEK 17,250m, a MM of 3.6x can be realized over the holding period. Sources of funds include SEK 5,693m (5.5x) debt and SEK 12,418m (12x) equity. | pt_PT |
| dc.identifier.tid | 203681460 | pt_PT |
| dc.identifier.uri | http://hdl.handle.net/10362/176338 | |
| dc.language.iso | eng | pt_PT |
| dc.relation | UID/ECO/00124/2013 | pt_PT |
| dc.subject | Private equity | pt_PT |
| dc.subject | Acquisition | pt_PT |
| dc.subject | Vitrolife | pt_PT |
| dc.subject | Leveraged buyout | pt_PT |
| dc.title | Vitrolife private equity investment committee paper - business plan | pt_PT |
| dc.type | master thesis | |
| dspace.entity.type | Publication | |
| rcaap.rights | openAccess | pt_PT |
| rcaap.type | masterThesis | pt_PT |
| thesis.degree.name | A Work Project, presented as part of the requirements for the Award of a Master’s degree in Finance from the Nova School of Business and Economics. | pt_PT |